intermediate-2/high risk Myelofibrosis

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

intermediate-2/high risk Myelofibrosis

Jul 2, 2024, 08:18 | Blog

Naveen Pemmaraju: Navitoclax and Ruxolitinib in Patients With Untreated Myelofibrosis

Naveen Pemmaraju shared a post on LinkedIn: “A huge shout out to all of you…

All: 1 Posts: 1 - 100

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

'

King Charles III Hospitalized Following Side Effects from Cancer Treatment

'

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023